EBS stock forecast, quote, news & analysis
Emergent BioSolutions Inc offers public health products to the government and healthcare providers... Show more
Why Emergent BioSolutions (EBS) Stock Is Down -15% in the Last 30 Days
Key Takeaways
- Emergent BioSolutions (EBS) shares declined approximately 15% over the last 30 days, falling from $8.53 on June 26, 2026, to $7.24 as of July 28, 2026.
- The stock has also dropped roughly 12% over the last quarter, extending a downtrend that began after the May 2026 highs near $9.50.
- Insider selling, elevated short interest exceeding 21% of float, and persistent concerns about year-over-year revenue declines have weighed heavily on investor sentiment.
- The company secured a $52.7 million ACAM2000 contract modification from the U.S. government in late June, but the positive development failed to reverse the broader selling pressure.
- All eyes are on the upcoming Q2 2026 earnings report scheduled for August 5, 2026, which could serve as a critical catalyst for the stock.
- Despite the negative price action, Wall Street analysts maintain a consensus Strong Buy rating with a $12 price target, implying significant upside from current levels.
Emergent BioSolutions (EBS) Company Overview and Market Position
Emergent BioSolutions is a specialty biopharmaceutical company focused on public health threats. Headquartered in Gaithersburg, Maryland, the company develops, manufactures, and delivers medical countermeasures (MCM) against biological and chemical threats, including vaccines and therapeutics for smallpox, mpox, anthrax, botulism, and Ebola. Its portfolio includes ACAM2000 (smallpox/mpox vaccine), BioThrax (anthrax vaccine), BAT (botulism antitoxin), ANTHRASIL, Ebanga, TEMBEXA, and raxibacumab. Emergent is also the maker of NARCAN Nasal Spray, the leading brand of naloxone for emergency opioid overdose reversal, available over the counter since 2023. With a 25-year track record of working with the U.S. government and allied nations, Emergent occupies a unique position in the biodefense landscape—bolstered by high barriers to entry, specialized manufacturing capabilities, and long-term government procurement contracts.
Emergent BioSolutions (EBS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, EBS stock has retreated approximately 15%. The decline began from a closing price of $8.53 on June 26, 2026—a session that saw a sharp 6.9% intraday bounce—and continued steadily through July, with the stock touching $7.24 by July 28. The most pronounced single-day drop occurred on July 14, when shares plunged 6.4% to $7.50 on above-average volume of roughly 1.2 million shares, more than 40% above the daily average.
Zooming out to the quarterly view, EBS has shed about 12% since late April 2026, when shares traded near $8.23. The stock did rally in May, reaching a quarterly peak around $9.50 on May 8, buoyed by the Q1 2026 earnings beat and a series of positive contract announcements. However, that momentum dissipated in June and July as broader headwinds—including insider transactions, persistent top-line revenue challenges, and high short interest—reasserted themselves. Year-to-date, EBS is down roughly 41%, reflecting the ongoing difficulty the company faces in convincing the market that its multi-year turnaround plan is taking hold.
What Drove EBS Stock Price in the Last 30 Days
Several converging factors explain the 30-day decline. First, insider selling activity has drawn scrutiny. On July 1, Senior Vice President Paul Anthony Williams sold 3,000 shares at a weighted average price of $8.40, a transaction disclosed via a Form 4 filing on July 2. This followed earlier sales in June by CFO Richard Lindahl, who sold 3,964 shares on June 8, and by board member Kathryn Zoon in May. While all transactions were executed under pre-arranged Rule 10b5-1 trading plans, the pattern of insider selling has contributed to negative sentiment.
Second, short interest in EBS remains exceptionally high at 21.17% of the float, with a days-to-cover ratio of approximately 8.0. Such elevated short positioning signals deep skepticism among bearish investors and can amplify downward price momentum during periods of low buying interest. Notably, short interest increased by 5% month-over-month heading into late July.
Third, the macroeconomic backdrop for small-cap biotech has been challenging. EBS, with a market capitalization of approximately $378 million, has been vulnerable to sector rotation pressure and reduced risk appetite. Revenue contraction remains a core concern: Q1 2026 revenue of $156.1 million reflected a 30% year-over-year decline, primarily due to the absence of a large international order that contributed roughly $60 million to Q1 2025 results. While the company beat EPS estimates and delivered adjusted EBITDA of $35.6 million, the persistent revenue headwinds have kept buyers cautious.
On the positive side, Emergent did secure a notable $52.7 million contract modification from the U.S. Department of Health and Human Services' ASPR on June 29 to supply ACAM2000 vaccine and ancillaries. However, the announcement generated only a brief bounce before the selling resumed.
What Drove EBS Stock Performance Over the Last Quarter
The quarterly decline reflects a broader narrative of mixed execution against ambitious turnaround goals. Emergent began the quarter on a relatively strong note, with shares trading near $8.23 in late April and rallying to $9.50 by early May following the Q1 2026 earnings report, which highlighted an EPS beat ($0.21 vs. -$0.25 consensus), debt refinancing that reduced interest costs, and a new $150 million term loan extending maturity to 2031. Investor conferences in late May and early June—including presentations at Jefferies and Goldman Sachs healthcare events—reinforced management's confidence in the multi-year transformation plan, international MCM expansion, and NARCAN product innovation.
Despite these positive signals, the stock steadily lost ground through June and July. The core tension for investors is the gap between management's cost-discipline success and the persistent revenue decline. Q1 revenue dropped 30% year-over-year, and full-year 2026 guidance of $720 million to $760 million implies flat to slightly declining top-line performance. Additionally, a $50.4 million contingent payment to Ridgeback Bio related to the Ebanga program was recorded as a current liability, reminding investors of balance sheet obligations. The combination of negative revenue momentum, aggressive short positioning, and ongoing insider selling has eroded the initial post-earnings optimism, pushing shares back toward the lower end of their recent trading range.
Trending AI Robots
In volatile markets like the one currently affecting Emergent BioSolutions, traders often turn to automated strategies to help navigate rapid price swings and sentiment shifts. Tickeron's Trending AI Robots page provides a curated view of top-performing AI-powered trading bots actively trading thousands of tickers across multiple strategies and timeframes. Each bot is designed with a distinct approach—ranging from short-term momentum plays to longer-duration trend-following models—and only the most relevant and consistently performing bots appear in this section. By filtering through hundreds of available AI trading bots, the Trending AI Robots page helps traders quickly identify strategies with proven performance metrics aligned to current market conditions. Exploring this resource can offer a data-driven complement to traditional analysis for those monitoring EBS and other actively traded names.
EBS Stock Forecast Drivers: What Investors Should Watch Next
The most consequential near-term event for EBS is the Q2 2026 earnings report scheduled for August 5, 2026. Investors will scrutinize revenue trends, particularly whether the MCM segment continues to benefit from international diversification—international MCM revenue reached 37% of the segment total in Q1—and whether NARCAN maintains its market share amid competitive pricing pressure. Any updates to full-year 2026 guidance, currently set at $720 million to $760 million in revenue and $155 million to $175 million in adjusted EBITDA, will be critical.
Beyond earnings, contract flow remains a key variable. Additional U.S. government procurement orders, progress on NATO and European Union stockpiling initiatives, and expansion of ACAM2000 into new international markets following recent regulatory approvals in Saudi Arabia and Singapore could provide catalysts. The company's debt reduction trajectory, stock buyback activity ($46.5 million remaining under the current authorization), and progress on the Substipharm Biologics manufacturing partnership for the Japanese Encephalitis vaccine also merit close attention. On the risk side, the elevated short interest creates the possibility of both further downside pressure and, conversely, a sharp short squeeze if positive catalysts materialize unexpectedly.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for EBS turns negative, indicating new downward trend
EBS saw its Momentum Indicator move below the 0 level on July 13, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In of the 86 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for EBS turned negative on July 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
EBS moved below its 50-day moving average on July 01, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EBS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for EBS entered a downward trend on July 31, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
EBS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.712) is normal, around the industry mean (47.256). P/E Ratio (8.849) is within average values for comparable stocks, (103.786). EBS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.832). EBS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (0.632) is also within normal values, averaging (115.273).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EBS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EBS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of biopharmaceutical products
Industry PharmaceuticalsGeneric